Feasibility of re‐biopsy and EGFR mutation analysis in patients with non‐small cell lung cancer
Feasibility of re‐biopsy and EGFR mutation analysis in patients with non‐small cell lung cancer
About this item
Full title
Author / Creator
Publisher
Melbourne: John Wiley & Sons Australia, Ltd
Journal title
Language
English
Formats
Publication information
Publisher
Melbourne: John Wiley & Sons Australia, Ltd
Subjects
More information
Scope and Contents
Contents
Background
In cases of EGFR‐tyrosine kinase inhibitor (TKI) failure, re‐biopsy may be useful to understand resistance mechanisms and guide further treatment decisions. However, performing re‐biopsy is challenging because of several hurdles. We assessed the feasibility of re‐biopsy in advanced non‐small cell lung cancer (NSCLC) patients in real‐w...
Alternative Titles
Full title
Feasibility of re‐biopsy and EGFR mutation analysis in patients with non‐small cell lung cancer
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6026616
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6026616
Other Identifiers
ISSN
1759-7706
E-ISSN
1759-7714
DOI
10.1111/1759-7714.12762
